Seer (SEER) 10-Q12 Aug 212021 Q2 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2021	Aug. 06, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-39747
Entity Registrant Name	SEER, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-1153150
Entity Address, Address Line One	3800 Bridge Parkway
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	650
Local Phone Number	453-0000
Title of 12(b) Security	Common Stock, par value $0.00001
Trading Symbol	SEER
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Central Index Key	0001726445
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Ex Transition Period	false
Class A common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		56,754,143
Class B common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		4,700,338

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 370,675	$ 333,585
Investments	147,098	98,278
Accounts receivable, net	896	0
Related party receivables	439	99
Other receivables	340	163
Inventory	2,670	551
Prepaid expenses and other current assets	3,208	452
Total current assets	525,326	433,128
Property and equipment, net	10,776	8,441
Restricted cash	524	343
Other assets	423	407
Total assets	537,049	442,319
Current liabilities:
Accounts payable	1,602	2,115
Accrued expenses	5,590	5,147
Accrued research and development	490	396
Deferred revenue	445	250
Deferred rent, current	228	186
Total current liabilities	8,355	8,094
Deferred rent, net of current portion	2,248	1,899
Other noncurrent liabilities	402	717
Total liabilities	11,005	10,710
Commitments (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of June 30, 2021 and December 31, 2020; zero shares issued and outstanding as of June 30, 2021 and December 31, 2020	0	0
Additional paid-in capital	614,483	486,915
Accumulated other comprehensive income (loss)	(34)	54
Accumulated deficit	(88,406)	(55,361)
Total stockholders’ equity	526,044	431,609
Total liabilities and stockholders’ equity	537,049	442,319
Class A common stock
Stockholders’ equity:
Common stock	1	1
Class B common stock
Stockholders’ equity:
Common stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Preferred stock, authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, authorized (in shares)	105,000,000
Common stock, issued (in shares)	61,423,263	59,261,051
Common stock, outstanding (in shares)	61,423,263	59,261,051
Class A common stock
Common stock, par value (usd per share)	$ 0.00001	$ 0.00001
Common stock, authorized (in shares)	94,000,000	94,000,000
Common stock, issued (in shares)	56,722,925	53,395,319
Common stock, outstanding (in shares)	56,722,925	53,395,319
Class B common stock
Common stock, par value (usd per share)	$ 0.00001	$ 0.00001
Common stock, authorized (in shares)	6,000,000	6,000,000
Common stock, issued (in shares)	4,700,338	5,865,732
Common stock, outstanding (in shares)	4,700,338	5,865,732

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 1,334	$ 71	$ 1,396	$ 248
Cost of revenue:
Total cost of revenue	586	0	586	0
Gross profit	748	71	810	248
Operating expenses:
Research and development	6,935	4,536	13,162	8,758
Selling, general and administrative	10,484	1,902	20,816	3,682
Total operating expenses	17,419	6,438	33,978	12,440
Loss from operations	(16,671)	(6,367)	(33,168)	(12,192)
Other income (expense):
Interest income	55	250	123	582
Total other income (expense)	55	250	123	582
Net loss	(16,616)	(6,117)	(33,045)	(11,610)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	(62)	(255)	(88)	278
Comprehensive loss	$ (16,678)	$ (6,372)	$ (33,133)	$ (11,332)
Net loss per share available to common shareholders, basic (in usd per share)	$ (0.27)	$ (0.63)	$ (0.55)	$ (1.25)
Net loss per share available to common shareholders, diluted (in usd per share)	$ (0.27)	$ (0.63)	$ (0.55)	$ (1.25)
Weighted-average common shares outstanding, basic (in shares)	60,841,657	9,718,393	60,367,433	9,320,520
Weighted average number of shares outstanding, diluted (in shares)	60,841,657	9,718,393	60,367,433	9,320,520
Product
Revenue:
Total revenue	$ 837	$ 0	$ 837	$ 0
Cost of revenue:
Total cost of revenue	504	0	504	0
Related party
Revenue:
Total revenue	380	0	380	0
Cost of revenue:
Total cost of revenue	82	0	82	0
Grant
Revenue:
Total revenue	$ 117	$ 71	$ 179	$ 248

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Class A and Class B Common Stock	Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2019		22,173,216	12,193,677
Beginning balance at Dec. 31, 2019	$ 87,679	$ 107,953	$ 0	$ 2,288	$ (22,586)	$ 24
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock from exercise of options (in shares)			40,207
Issuance of Class A common stock from exercise of options	24			24
Vesting of early exercised stock options and restricted common stock	4			4
Stock-based compensation	579			579
Other comprehensive income	533					533
Net loss	(5,493)				(5,493)
Ending balance (in shares) at Mar. 31, 2020		22,173,216	12,233,884
Ending balance at Mar. 31, 2020	83,326	$ 107,953	$ 0	2,895	(28,079)	557
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock from exercise of options (in shares)			11,877
Issuance of Class A common stock from exercise of options	28			28
Repurchase of Class A common stock (in shares)			(215,245)
Repurchase of Class A common stock	0
Vesting of early exercised stock options and restricted common stock	10			10
Issuance of stock (in shares)		6,853,571
Issuance of stock	54,896	$ 54,896
Stock-based compensation	808			808
Other comprehensive income	(255)					(255)
Net loss	(6,117)				(6,117)
Ending balance (in shares) at Jun. 30, 2020		29,026,787	12,030,516
Ending balance at Jun. 30, 2020	$ 132,696	$ 162,849	$ 0	3,741	(34,196)	302
Beginning balance (in shares) at Dec. 31, 2020	59,261,051	0	59,261,051
Beginning balance at Dec. 31, 2020	$ 431,609	$ 0	$ 1	486,915	(55,361)	54
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock from exercise of options (in shares)			399,174
Issuance of Class A common stock from exercise of options	171			171
Repurchase of Class A common stock (in shares)			(876)
Vesting of early exercised stock options and restricted common stock	44			44
Issuance of stock (in shares)			1,650,000
Issuance of stock	102,959			102,959
Return of profit	11,403			11,403
Stock-based compensation	6,039			6,039
Other comprehensive income	(26)					(26)
Net loss	(16,429)				(16,429)
Ending balance (in shares) at Mar. 31, 2021		0	61,309,349
Ending balance at Mar. 31, 2021	$ 535,770	$ 0	$ 1	607,531	(71,790)	28
Beginning balance (in shares) at Dec. 31, 2020	59,261,051	0	59,261,051
Beginning balance at Dec. 31, 2020	$ 431,609	$ 0	$ 1	486,915	(55,361)	54
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock from exercise of options (in shares)	530,178
Ending balance (in shares) at Jun. 30, 2021	61,423,263	0	61,423,263
Ending balance at Jun. 30, 2021	$ 526,044	$ 0	$ 1	614,483	(88,406)	(34)
Beginning balance (in shares) at Mar. 31, 2021		0	61,309,349
Beginning balance at Mar. 31, 2021	535,770	$ 0	$ 1	607,531	(71,790)	28
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock from exercise of options (in shares)			132,766
Issuance of Class A common stock from exercise of options	236			236
Repurchase of Class A common stock (in shares)			(18,852)
Vesting of early exercised stock options and restricted common stock	285			285
Stock-based compensation	6,431			6,431
Other comprehensive income	(62)					(62)
Net loss	$ (16,616)				(16,616)
Ending balance (in shares) at Jun. 30, 2021	61,423,263	0	61,423,263
Ending balance at Jun. 30, 2021	$ 526,044	$ 0	$ 1	$ 614,483	$ (88,406)	$ (34)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Parentheticals) - USD ($) $ in Thousands	Feb. 01, 2021	Mar. 31, 2021	Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]
Offering transaction costs	$ 7,600	$ 7,591	$ 104

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (33,045)	$ (11,610)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	12,470	1,387
Depreciation and amortization	1,042	701
Net amortization of premium on available-for-sale securities	412	100
Changes in operating assets and liabilities:
Accounts receivable, net	(896)	0
Related party receivables	(340)	0
Other receivables	(177)	(315)
Prepaid expenses and other current assets	(2,756)	78
Inventory	(2,119)	0
Other assets	(16)	(48)
Accounts payable	(644)	(82)
Deferred revenue	195	250
Deferred rent	391	269
Accrued expenses	241	(477)
Accrued research and development	94	(106)
Other noncurrent liabilities	(74)	0
Net cash used in operating activities	(25,222)	(9,853)
INVESTING ACTIVITIES
Purchases of property and equipment	(2,943)	(3,542)
Purchase of available-for-sale securities	(129,320)	(3,437)
Proceeds from maturities of available-for-sale securities	80,000	17,250
Net cash provided by (used in) investing activities	(52,263)	10,271
FINANCING ACTIVITIES
Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs	102,959	0
Proceeds from return of profit	11,403	0
Repurchase of Class A common stock	(13)	(7)
Proceeds from stock option exercises including early exercised options	407	72
Proceeds from issuance of Series D-1 preferred stock, net of issuance costs	0	54,975
Net cash provided by financing activities	114,756	55,040
Net increase in cash, cash equivalents and restricted cash	37,271	55,458
Cash, cash equivalents and restricted cash, beginning of period	333,928	17,828
Cash, cash equivalents and restricted cash, end of period	371,199	73,286
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for income taxes	441	0
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible preferred stock issuance costs included in accounts payable	0	79
Accounts Payable
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases included in balance sheet locations	246	76
Accrued Liabilities
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases included in balance sheet locations	$ 361	$ 3

Organization and Description of

Organization and Description of the Business	6 Months Ended
Organization and Description of the Business	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	ORGANIZATION AND DESCRIPTION OF THE BUSINESS Seer, Inc. (the Company) was incorporated in Delaware on March 16, 2017, and is based in Redwood City, California. In December 2020, the Company formed the wholly-owned subsidiary, Seer Securities Corporation, located in Massachusetts. The Company is a life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company is subject to a number of risks, similar to other early-stage life science companies, including, but not limited to, development and commercialization of its products, market acceptance of its products, development by its competitors of new technological innovations, protection of its intellectual property, and raising additional capital. Public Offering On February 1, 2021, the Company completed an underwritten public offering of 1,650,000 shares of its Class A common stock at a public offering price of $67.00 per share. The Company received net proceeds of $103.0 million after deducting offering costs, underwriting discounts, and commissions of $7.6 million. Reverse Stock Split In November 2020, the Company’s board of directors approved an amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock and convertible preferred stock on a 1-for-2.14 basis (the Reverse Stock Split) effective as of November 25, 2020. The par values of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, restricted stock awards, restricted stock units, convertible preferred stock, share data, per share data, and related information contained in the unaudited condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Liquidity As of June 30, 2021, the Company has incurred significant losses and has had negative cash flows from operations. As of June 30, 2021, the Company had cash, cash equivalents and investments of $517.8 million and an accumulated deficit of $88.4 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of June 30, 2021 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has issued shares of Class A common stock, herein referred to as “Class A common stock” or “Class A,” and Class B common stock, herein referred to as “Class B common stock” or “Class B,” and collectively as “common stock.” The unaudited condensed consolidated financial statements include the accounts of Seer, Inc. and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2020 included in the Annual Report on Form 10-K filed with the SEC on March 29, 2021. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including, but not limited to, those related to the determination of stand-alone selling price for revenue recognition, the fair value of common stock, stock-based compensation, accrued research and development expenses, allowance for credit losses, inventory valuation, useful lives and valuation of property and equipment, income tax uncertainties, and tax valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. Impact of the COVID-19 Pandemic As a result of the COVID-19 pandemic (COVID-19), the Company’s operations experienced disruptions and restrictions on employees’ ability to work and on the hiring of additional personnel, particularly as a result of preventive and precautionary measures taken by the Company and some of its suppliers and other service providers. In particular, some of the Company’s laboratory material and equipment suppliers, collaborators, and service providers used in the performance of its research activities and phased commercial launch plan have been similarly impacted by COVID-19, which may limit the Company’s ability to achieve its planned progress. COVID-19 has adversely affected the broader economy, which could affect the Company’s financing prospects. Continued disruptions from COVID-19 could harm the Company’s operations and the Company cannot anticipate all the ways in which it could be adversely impacted by health epidemics such as COVID-19. The COVID-19 pandemic has mainly impacted the progress of research and development activities due to the limited ability of the Company’s employees to access laboratories during times of statewide quarantine and on some of its suppliers who have experienced a surge in demand for their products resulting in supply delays for critical hardware, instrumentation and medical and testing supplies used for product development. The Company continues to monitor and assess the effects of the COVID-19 pandemic on its business, financial condition, results of operations and cash flows. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of June 30, 2021 and December 31, 2020, all amounts recorded as cash and cash equivalents consist of money market funds and are stated at fair value. Restricted cash as of June 30, 2021 and December 31, 2020 represents cash held by a financial institution as security for a letter of credit issued to the lessor for one of the Company’s operating leases and is classified as non-current. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands): June 30, December 31, 2021 2020 Cash and cash equivalents $ 370,675 $ 333,585 Restricted cash 524 343 Total cash, cash equivalents and restricted cash $ 371,199 $ 333,928 Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services, net of any allowance for credit losses. The Company’s expected loss allowance methodology for receivables is developed using its historical collection experience, current and future economic market conditions and a review of the current aging status and financial condition of its customers. Specific allowance amounts are established to record the appropriate allowance for customers that have an identified risk of default. General allowance amounts are established based upon an assessment of expected credit losses for the Company’s receivables by aging category. Balances are written off when they are ultimately determined to be uncollectible. There was no allowance for credit losses related to accounts receivable as of June 30, 2021 and December 31, 2020. Inventory Inventory is recorded at the lower of standard cost, which approximates actual cost on a weighted-average basis, or net realizable value. Provisions for slow-moving, excess or obsolete inventories are recorded when required to reduce inventory values to their estimated net realizable values based on product expiration, development plans, or quality issues. Revenue Recognition Product and Service Revenue The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company began shipping its Proteograph Product Suite and consumable kits during the second quarter of 2021. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity and not a separate performance obligation. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 or 60 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Grant Revenue Grant revenue represents funding under cost reimbursement programs from federal foundation sources for qualified research and development activities performed by the Company and are not based on estimates that are subject to change. Grants received are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Such amounts are recorded as revenue as grant-funded activities are performed up to the amount of expenses incurred. Any advance funding payments are recorded as deferred revenue until the activities are performed. Shipping and Handling Costs Shipping and handling costs are included in cost of revenue. Stock-Based Compensation The Company accounts for stock-based compensation, including from restricted common stock awards (RSAs), grants of restricted stock units (RSUs), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of RSAs is the difference between the fair value of the underlying stock at the measurement date and the purchase price. The fair value of RSUs is the fair value of the underlying stock at the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For share-based payment awards that vest subject to the satisfaction of a service requirement, the fair value of the awards is recognized as expense on a straight-line basis over the requisite service period in which the awards are expected to vest. For share-based payment awards with performance-based vesting conditions, the fair value of the awards is recognized as expense using the accelerated attribution method over the vesting period. Forfeitures are accounted for in the period in which they occur. Share-based payment awards that include a service condition and a performance condition are expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards that require judgment, for which changes if they occur can materially affect the resulting estimates of fair value. These assumptions include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield, and the expected stock price volatility over the expected term as follows: Fair Value of Common Stock For grants prior to the Company’s initial public offering (IPO) in December 2020, the grant-date fair market value of the shares of common stock underlying stock options was determined by the Company’s Board of Directors with assistance of third-party valuation specialists. Because there was no public market for the Company’s common stock, the Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which include important developments in the Company’s operations, the prices at which the Company sold shares of its convertible preferred stock, the rights, preferences and privileges of the Company’s convertible preferred stock relative to those of the Company’s common stock, actual operating results, financial performance, external market conditions in the life sciences industry, general U.S. market conditions, equity market conditions of comparable public companies, and the lack of marketability of the Company’s common stock. For all grants subsequent to the IPO, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Select Market. Expected Volatility The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The historical volatility is calculated based on a period of time commensurate with the expected term assumptions. Expected Term For stock options granted to employees and directors, the expected term is calculated using the simplified method for “plain vanilla” stock option awards. The expected term for stock options granted to non-employees is the contractual term. Risk-Free Interest Rate The risk-free interest rate is based on the yield available on U.S. Treasury issues similar in duration to the expected term of the equity-settled award. Expected Dividends The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay dividends on its common stock. Net Loss Per Share Attributable to Common Stockholders Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis. The Company’s participating securities include the Company’s convertible preferred stock that was outstanding prior to the completion of the Company’s IPO, as the holders were entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify the accounting for income taxes. This standard removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing standards to improve consistent application. The Company adopted this standard as of January 1, 2021, which did not have a material impact on its financial statements as of the adoption date. In January 2020, the FASB issued ASU No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . This standard clarifies the interaction between accounting standards related to equity securities, equity method investments, and certain derivative instruments. The Company adopted this standard as of January 1, 2021, which did not have a material impact on its financial statements as of the adoption date. Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This standard clarifies the definition of a lease and requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-to-use asset representing its right to use the underlying asset for the lease term. The Company anticipates that it will no longer qualify as an emerging growth company as of December 31, 2021, and will first present the application of this standard in its annual financial statements for the year ended December 31, 2021. While the Company has not yet quantified the impact, these adjustments will increase total assets and total liabilities relative to such amounts reported prior to adoption.

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments	FAIR VALUE MEASUREMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS The following tables set forth the fair value of the Company’s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). June 30, 2021 Level 1 Level 2 Level 3 Total Assets: Classification: Money market funds Cash and cash equivalents $ 369,580 $ — $ — $ 369,580 U.S. Treasury securities Investments — 147,098 — 147,098 Total assets measured at fair value $ 369,580 $ 147,098 $ — $ 516,678 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Classification: Money market funds Cash and cash equivalents $ 333,585 $ — $ — $ 333,585 U.S. Treasury securities Investments — 98,278 — 98,278 Total assets measured at fair value $ 333,585 $ 98,278 $ — $ 431,863 There were no financial liabilities measured at fair value. The Company classifies money market funds within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company classifies its investments in U.S. Treasury securities (Treasury bills, Treasury notes, and Treasury bonds) as Level 2 instruments and obtains fair value from an independent pricing service, which may use quoted market prices for identical or comparable instruments or model-driven valuations using observable market data or inputs corroborated by observable market data. The carrying amount of the Company’s accounts receivable, other receivables, prepaid expenses, other current assets, accounts payable, and accrued expenses approximate fair value due to their short maturities. The following is a summary of the Company’s cash equivalents and investments and the gross unrealized holding gains and losses (in thousands): June 30, 2021 Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Assets: Money market funds $ 369,580 $ — $ — $ 369,580 U.S. Treasury securities 147,132 10 (44) 147,098 Total $ 516,712 $ 10 $ (44) $ 516,678 December 31, 2020 Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Assets: Money market funds $ 333,585 $ — $ — $ 333,585 U.S. Treasury securities 98,223 57 (2) 98,278 Total $ 431,808 $ 57 $ (2) $ 431,863

Other Financial Statement Infor

Other Financial Statement Information	6 Months Ended
Other Financial Statement Information	Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Other Financial Statement Information	OTHER FINANCIAL STATEMENT INFORMATION Inventory Inventory consists of the following (in thousands): June 30, December 31, 2021 2020 Raw materials $ 1,833 $ — Finished goods 837 551 Total inventory $ 2,670 $ 551 Property and Equipment, Net Property and equipment, net consists of the following (in thousands): June 30, December 31, 2021 2020 Laboratory equipment $ 10,893 $ 8,075 Computer equipment and software 429 182 Furniture and fixtures 478 241 Leasehold improvements 2,369 2,294 Property and equipment 14,169 10,792 Less: accumulated depreciation and amortization 3,393 2,351 Total property and equipment, net $ 10,776 $ 8,441 Depreciation and amortization expense related to property and equipment was $0.6 million and $0.4 million for the three months ended June 30, 2021 and 2020, respectively. Depreciation and amortization expense related to property and equipment was $1.0 million and $0.7 million for the six months ended June 30, 2021 and 2020, respectively. Accrued Expenses Accrued expenses consist of the following (in thousands): June 30, December 31, 2021 2020 Accrued compensation $ 2,486 $ 2,866 Accrued professional services 374 1,074 Accrued property and equipment 361 — Accrued inventory purchases 1,037 — Restricted stock liability, current 383 484 Other 949 723 Total accrued expenses $ 5,590 $ 5,147

Revenue and Deferred Revenue

Revenue and Deferred Revenue	6 Months Ended
Revenue and Deferred Revenue	Jun. 30, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Revenue and Deferred Revenue	REVENUE AND DEFERRED REVENUE Product revenue consists of instruments, consumables and platform evaluation agreements. Related party revenue is comprised of both the sale of products and services performed. As of June 30, 2021 and December 31, 2020, the Company recorded $0.4 million and $0.3 million of contract liabilities, consisting of deferred revenue. None of the revenue recorded in the six months ended June 30, 2021 was included in contract liabilities as of December 31, 2020. All contract liabilities are expected to be recognized as revenue in the next twelve months. Research Agreements In February 2019 and March 2020, the Company entered into sponsored research agreements with a biotechnology company and a pharmaceutical company, respectively, under which the Company is required to execute certain research and development activities for total aggregate consideration payable of $0.9 million. During the three and six months ended June 30, 2021 and 2020, the Company did not recognize any revenue with respect to these agreements. NIH Grant In August 2019, the Company received a notice of a Small Business Innovation Research grant award from the National Institutes of Health, which will provide funding of approximately $1.1 million to the Company for its development of research applications. In June 2020, the Company received a notice that additional grant consideration of $0.9 million will be awarded. During the three months ended June 30, 2021 and 2020, the Company recognized grant revenue of $0.1 million and $0.1 million, respectively, with respect to the award. During the six months ended June 30, 2021 and 2020, the Company recognized grant revenue of $0.2 million and $0.2 million, respectively, with respect to the award.

Capital Stock and Stockholders'

Capital Stock and Stockholders' Equity	6 Months Ended
Capital Stock and Stockholders' Equity	Jun. 30, 2021
Equity [Abstract]
Capital Stock and Stockholders' Equity	CAPITAL STOCK AND STOCKHOLDERS’ EQUITY As of June 30, 2021, the Company is authorized to issue 105,000,000 shares of capital stock consisting of 94,000,000 shares of Class A common stock, 6,000,000 shares of Class B common stock, and 5,000,000 shares of preferred stock. Common Stock Common stock issued and outstanding is as follows: June 30, December 31, 2021 2020 Class A common stock 56,722,925 53,395,319 Class B common stock 4,700,338 5,865,732 Total common stock issued and outstanding 61,423,263 59,261,051 Class A and Class B common stock have a par value of $0.00001 per share. Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to 10 votes per share. Class B common shares are convertible to Class A common shares at any time at the option of the holder on a one-for-one basis. Holders of common stock are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. In the first quarter of 2021, the Company received $11.4 million related to the return of short-swing profits from one of its beneficial owners. These proceeds are recognized as a capital contribution from stockholders as an increase to additional paid-in capital on the condensed consolidated statements of changes in stockholders’ equity and as cash provided by financing activities on the condensed consolidated statements of cash flows.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
Equity Incentive Plans	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	EQUITY INCENTIVE PLANS In 2017, the Company adopted the 2017 Stock Incentive Plan (2017 Plan), which provided for the granting of awards to employees, directors, and consultants of the Company. Awards issuable under the Plan include incentive stock options (ISO), nonqualified stock options (NSO), and restricted stock awards. In 2020, the Company adopted the 2020 RSU Equity Incentive Plan (2020 RSU Plan), which provided for the granting of RSUs to certain employees of the Company. In 2020, the Company adopted the 2020 Equity Incentive Plan (2020 Plan), which became effective in connection with the IPO. The Company’s 2017 Plan and 2020 RSU Plan were terminated in connection with the IPO and no further grants will be made under the 2017 Plan and 2020 RSU Plan from the date that the 2020 Plan became effective. As of June 30, 2021, there are 8,302,701 shares of Class A common stock reserved for issuance under the 2020 Plan of which 5,965,116 shares are available for issuance in connection with grants of future awards. Stock option activity for the six months ended June 30, 2021 is as follows: Options Outstanding Weighted Average Exercise Price Balance - December 31, 2020 9,551,105 $ 5.55 Options granted 1,015,699 54.65 Options exercised (530,178) 0.77 Options cancelled and forfeited (139,424) 18.81 Balance - June 30, 2021 9,897,202 $ 10.66 Vested and exercisable, June 30, 2021 2,128,772 $ 3.44 Restricted Stock Certain stock options granted under the 2017 Plan provide stock option holders the right to exercise unvested stock options in exchange for restricted shares of Class A common stock. The Company has also issued restricted shares of Class A common stock to employees and directors under the 2017 Plan. The activity of restricted shares of Class A common stock for the six months ended June 30, 2021 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Unvested at December 31, 2020 775,641 $ 1.77 Granted 10,728 1.66 Repurchased (19,728) 1.14 Vested (340,196) 1.62 Unvested at June 30, 2021 426,445 $ 1.92 RSUs The Company has granted RSUs under the 2020 RSU Plan and the 2020 Plan. RSU activity for the six months ended June 30, 2021 is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Balance at December 31, 2020 491,318 $ 7.91 Granted 253,883 56.66 Vested (1,762) 43.39 Cancelled (3,543) 19.00 Balance at June 30, 2021 739,896 $ 24.50 Employee Stock Purchase Plan In November 2020, the Company’s board of directors adopted the 2020 Employee Stock Purchase Plan (ESPP), which was subsequently approved by the Company’s stockholders and became effective in connection with the IPO. A total of 1,195,327 shares of Class A common stock are reserved for issuance under the ESPP as of June 30, 2021. The first offering period has not commenced as of June 30, 2021 and there is no stock-based compensation related to the ESPP for the three months ended June 30, 2021. Stock-Based Compensation The following table summarizes the components of stock-based compensation recognized in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Cost of revenue $ 344 $ — $ 747 $ — Research and development 1,098 170 2,187 351 Selling, general and administrative 4,989 638 9,535 1,036 Total stock-based compensation $ 6,431 $ 808 $ 12,469 $ 1,387

Commitments

Commitments	6 Months Ended
Commitments	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments	COMMITMENTS Facility Lease Agreement On January 4, 2019, the Company entered into a lease agreement for office and laboratory space in Redwood City, California. The lease term commenced in November 2019 and ends on September 30, 2029. In connection with the lease and its amendments, the Company maintains a letter of credit issued to the lessor in the amount of $0.5 million, which is secured by restricted cash that is classified as non-current at June 30, 2021 and December 31, 2020 based on the term of the underlying lease. The Company entered into an amendment to the lease agreement with respect to its facility in Redwood City, California in June 2020. The amendment makes certain changes to the original lease, including (i) additional office and laboratory space in the same building (Expansion Premises) and (ii) an extension of the expiration date of the original lease to 127.5 months following the delivery date of the Expansion Premises, which is estimated to be in the fourth quarter of 2021. The amendment provides for annual base rent for the Expansion Premises of approximately $0.9 million in the first year of the lease term (subject to an abatement period of nine months), which increases on an annual basis to approximately $1.2 million in the final year of the lease term. The amendment also provides for tenant incentives in the amount of $2.4 million. Under the amendment, the Company retains its original option to renew the lease for an additional five-year term, at then-current market rates. During the period from the lease amendment commencement until the earlier of one month after occupancy of the Expansion Premises or September 2021, the Company will be provided with temporary space. The Company is not required to pay additional rent for the temporary space, but is required to pay property taxes, insurance and normal maintenance costs with respect to the temporary space. The Company entered into another amendment to the lease agreement with respect to its facility in Redwood City, California in April 2021. The amendment expanded the office and laboratory space by approximately 25,000 square feet, commenced in May 2021, and has a term of approximately 11 years. Rent expense was $0.6 million and $0.2 million for the three months ended June 30, 2021 and 2020, respectively. Rent expense was $0.8 million and $0.3 million for the six months ended June 30, 2021 and 2020, respectively. The Company is required to pay property taxes, insurance, and normal maintenance costs for the facility and will be required to pay any increases over the base year of these expenses. As of June 30, 2021, future minimum commitments under the Company’s non-cancelable facility operating lease are as follows: Years ending December 31, (in thousands) 2021 (six months remaining) $ 398 2022 2,517 2023 3,642 2024 3,747 2025 3,856 Thereafter 27,013 Total $ 41,173 Purchase Commitments and Obligations The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order within a certain time period. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or subject to change. These outstanding commitments amounted to $5.1 million and $3.1 million as of June 30, 2021 and December 31, 2020, respectively, and are excluded from the future minimum commitments table above. Guarantees and Indemnifications In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of the status or service as directors or officers. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of June 30, 2021 and December 31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. Contingencies From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings.

Prognomiq, Inc.

Prognomiq, Inc.	6 Months Ended
Prognomiq, Inc.	Jun. 30, 2021
Related Party Transactions [Abstract]
Prognomiq, Inc.	PROGNOMIQ, INC. In August 2020, the Company formed a new entity, PrognomIQ, Inc. (PrognomIQ), and entered into a stock purchase agreement with PrognomIQ, pursuant to which the Company transferred to PrognomIQ certain assets that comprise the Company’s human diagnostics activities in exchange for all the outstanding equity interests of PrognomIQ. The Company subsequently completed a pro-rata distribution to its stockholders of most of the shares of capital stock of PrognomIQ. The Company has concluded that PrognomIQ is a VIE due to its reliance on future financing and insufficient equity investment at risk. However, the Company is not the primary beneficiary of the VIE as it does not have the power to direct the activities that most significantly impact the economic performance of PrognomIQ and does not have control over the PrognomIQ board of directors. The Company has determined that it has the ability to exercise significant influence over PrognomIQ and therefore has accounted for its investment in PrognomIQ using the equity method. During the year ended December 31, 2020, the carrying value of the Company’s investment in PrognomIQ was reduced to nil after recognizing net losses based on its percentage of ownership in PrognomIQ. PrognomIQ constitutes a related party and, as of June 30, 2021 and December 31, 2020, the Company recorded $0.4 million and $0.1 million in related party receivables, respectively, on the condensed consolidated balance sheets representing amounts due from product sales and services and for general transition services and support provided. Revenue received from PrognomIQ is recorded as related party revenue on the condensed consolidated statements of operations and comprehensive loss and is comprised of both the sale of consumables and services performed.

Net Loss Per Share Attributable

Net Loss Per Share Attributable To Common Stockholders	6 Months Ended
Net Loss Per Share Attributable To Common Stockholders	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable To Common Stockholders	NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data): Three Months Ended Six Months Ended 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ (16,616) $ (6,117) $ (33,045) $ (11,610) Denominator: Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 60,841,657 9,718,393 60,367,433 9,320,520 Net loss per share attributable to common stockholders, basic and diluted $ (0.27) $ (0.63) $ (0.55) $ (1.25) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis): Three Months Ended Six Months Ended 2021 2020 2021 2020 Convertible preferred stock — 29,026,787 — 29,026,787 Class A common stock options issued and outstanding 9,897,202 6,340,390 9,897,202 6,340,390 Restricted common stock subject to future vesting 426,445 1,886,297 426,445 1,886,297 Restricted stock units 739,896 101,510 739,896 101,510 Total 11,063,543 37,354,984 11,063,543 37,354,984

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has issued shares of Class A common stock, herein referred to as “Class A common stock” or “Class A,” and Class B common stock, herein referred to as “Class B common stock” or “Class B,” and collectively as “common stock.” The unaudited condensed consolidated financial statements include the accounts of Seer, Inc. and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including, but not limited to, those related to the determination of stand-alone selling price for revenue recognition, the fair value of common stock, stock-based compensation, accrued research and development expenses, allowance for credit losses, inventory valuation, useful lives and valuation of property and equipment, income tax uncertainties, and tax valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of June 30, 2021 and December 31, 2020, all amounts recorded as cash and cash equivalents consist of money market funds and are stated at fair value. Restricted cash as of June 30, 2021 and December 31, 2020 represents cash held by a financial institution as security for a letter of credit issued to the lessor for one of the Company’s operating leases and is classified as non-current.
Accounts Receivable, Net	Accounts Receivable, NetAccounts receivable consist of amounts due from customers for the sales of products and services, net of any allowance for credit losses. The Company’s expected loss allowance methodology for receivables is developed using its historical collection experience, current and future economic market conditions and a review of the current aging status and financial condition of its customers. Specific allowance amounts are established to record the appropriate allowance for customers that have an identified risk of default. General allowance amounts are established based upon an assessment of expected credit losses for the Company’s receivables by aging category. Balances are written off when they are ultimately determined to be uncollectible.
Inventory	Inventory Inventory is recorded at the lower of standard cost, which approximates actual cost on a weighted-average basis, or net realizable value. Provisions for slow-moving, excess or obsolete inventories are recorded when required to reduce inventory values to their estimated net realizable values based on product expiration, development plans, or quality issues.
Revenue Recognition	Revenue Recognition Product and Service Revenue The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company began shipping its Proteograph Product Suite and consumable kits during the second quarter of 2021. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity and not a separate performance obligation. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 or 60 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Grant Revenue Grant revenue represents funding under cost reimbursement programs from federal foundation sources for qualified research and development activities performed by the Company and are not based on estimates that are subject to change. Grants received are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Such amounts are recorded as revenue as grant-funded activities are performed up to the amount of expenses incurred. Any advance funding payments are recorded as deferred revenue until the activities are performed. Shipping and Handling Costs Shipping and handling costs are included in cost of revenue.
Stock-based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation, including from restricted common stock awards (RSAs), grants of restricted stock units (RSUs), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of RSAs is the difference between the fair value of the underlying stock at the measurement date and the purchase price. The fair value of RSUs is the fair value of the underlying stock at the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For share-based payment awards that vest subject to the satisfaction of a service requirement, the fair value of the awards is recognized as expense on a straight-line basis over the requisite service period in which the awards are expected to vest. For share-based payment awards with performance-based vesting conditions, the fair value of the awards is recognized as expense using the accelerated attribution method over the vesting period. Forfeitures are accounted for in the period in which they occur. Share-based payment awards that include a service condition and a performance condition are expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards that require judgment, for which changes if they occur can materially affect the resulting estimates of fair value. These assumptions include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield, and the expected stock price volatility over the expected term as follows: Fair Value of Common Stock For grants prior to the Company’s initial public offering (IPO) in December 2020, the grant-date fair market value of the shares of common stock underlying stock options was determined by the Company’s Board of Directors with assistance of third-party valuation specialists. Because there was no public market for the Company’s common stock, the Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which include important developments in the Company’s operations, the prices at which the Company sold shares of its convertible preferred stock, the rights, preferences and privileges of the Company’s convertible preferred stock relative to those of the Company’s common stock, actual operating results, financial performance, external market conditions in the life sciences industry, general U.S. market conditions, equity market conditions of comparable public companies, and the lack of marketability of the Company’s common stock. For all grants subsequent to the IPO, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Select Market. Expected Volatility The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The historical volatility is calculated based on a period of time commensurate with the expected term assumptions. Expected Term For stock options granted to employees and directors, the expected term is calculated using the simplified method for “plain vanilla” stock option awards. The expected term for stock options granted to non-employees is the contractual term. Risk-Free Interest Rate The risk-free interest rate is based on the yield available on U.S. Treasury issues similar in duration to the expected term of the equity-settled award. Expected Dividends The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay dividends on its common stock.
Net Loss Per Share Attributable to Common Shareholders	Net Loss Per Share Attributable to Common Stockholders Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis. The Company’s participating securities include the Company’s convertible preferred stock that was outstanding prior to the completion of the Company’s IPO, as the holders were entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify the accounting for income taxes. This standard removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing standards to improve consistent application. The Company adopted this standard as of January 1, 2021, which did not have a material impact on its financial statements as of the adoption date. In January 2020, the FASB issued ASU No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . This standard clarifies the interaction between accounting standards related to equity securities, equity method investments, and certain derivative instruments. The Company adopted this standard as of January 1, 2021, which did not have a material impact on its financial statements as of the adoption date. Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This standard clarifies the definition of a lease and requires a lessee to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-to-use asset representing its right to use the underlying asset for the lease term. The Company anticipates that it will no longer qualify as an emerging growth company as of December 31, 2021, and will first present the application of this standard in its annual financial statements for the year ended December 31, 2021. While the Company has not yet quantified the impact, these adjustments will increase total assets and total liabilities relative to such amounts reported prior to adoption.
Fair Value Measurements	There were no financial liabilities measured at fair value. The Company classifies money market funds within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company classifies its investments in U.S. Treasury securities (Treasury bills, Treasury notes, and Treasury bonds) as Level 2 instruments and obtains fair value from an independent pricing service, which may use quoted market prices for identical or comparable instruments or model-driven valuations using observable market data or inputs corroborated by observable market data. The carrying amount of the Company’s accounts receivable, other receivables, prepaid expenses, other current assets, accounts payable, and accrued expenses approximate fair value due to their short maturities.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands): June 30, December 31, 2021 2020 Cash and cash equivalents $ 370,675 $ 333,585 Restricted cash 524 343 Total cash, cash equivalents and restricted cash $ 371,199 $ 333,928

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets Measured on Recurring Basis	The following tables set forth the fair value of the Company’s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). June 30, 2021 Level 1 Level 2 Level 3 Total Assets: Classification: Money market funds Cash and cash equivalents $ 369,580 $ — $ — $ 369,580 U.S. Treasury securities Investments — 147,098 — 147,098 Total assets measured at fair value $ 369,580 $ 147,098 $ — $ 516,678 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Classification: Money market funds Cash and cash equivalents $ 333,585 $ — $ — $ 333,585 U.S. Treasury securities Investments — 98,278 — 98,278 Total assets measured at fair value $ 333,585 $ 98,278 $ — $ 431,863
Schedule of Debt Securities, Available-for-sale, Unrealized Gain	The following is a summary of the Company’s cash equivalents and investments and the gross unrealized holding gains and losses (in thousands): June 30, 2021 Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Assets: Money market funds $ 369,580 $ — $ — $ 369,580 U.S. Treasury securities 147,132 10 (44) 147,098 Total $ 516,712 $ 10 $ (44) $ 516,678 December 31, 2020 Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Assets: Money market funds $ 333,585 $ — $ — $ 333,585 U.S. Treasury securities 98,223 57 (2) 98,278 Total $ 431,808 $ 57 $ (2) $ 431,863

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	6 Months Ended
Other Financial Statement Information (Tables)	Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventory	Inventory consists of the following (in thousands): June 30, December 31, 2021 2020 Raw materials $ 1,833 $ — Finished goods 837 551 Total inventory $ 2,670 $ 551
Schedule of Property and Equipment	Property and equipment, net consists of the following (in thousands): June 30, December 31, 2021 2020 Laboratory equipment $ 10,893 $ 8,075 Computer equipment and software 429 182 Furniture and fixtures 478 241 Leasehold improvements 2,369 2,294 Property and equipment 14,169 10,792 Less: accumulated depreciation and amortization 3,393 2,351 Total property and equipment, net $ 10,776 $ 8,441
Schedule of Accrued Liabilities	Accrued expenses consist of the following (in thousands): June 30, December 31, 2021 2020 Accrued compensation $ 2,486 $ 2,866 Accrued professional services 374 1,074 Accrued property and equipment 361 — Accrued inventory purchases 1,037 — Restricted stock liability, current 383 484 Other 949 723 Total accrued expenses $ 5,590 $ 5,147

Capital Stock and Stockholder_2

Capital Stock and Stockholders' Equity (Tables)	6 Months Ended
Capital Stock and Stockholders' Equity (Tables)	Jun. 30, 2021
Equity [Abstract]
Schedule of Stock by Class	Common stock issued and outstanding is as follows: June 30, December 31, 2021 2020 Class A common stock 56,722,925 53,395,319 Class B common stock 4,700,338 5,865,732 Total common stock issued and outstanding 61,423,263 59,261,051

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
Equity Incentive Plans (Tables)	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	Stock option activity for the six months ended June 30, 2021 is as follows: Options Outstanding Weighted Average Exercise Price Balance - December 31, 2020 9,551,105 $ 5.55 Options granted 1,015,699 54.65 Options exercised (530,178) 0.77 Options cancelled and forfeited (139,424) 18.81 Balance - June 30, 2021 9,897,202 $ 10.66 Vested and exercisable, June 30, 2021 2,128,772 $ 3.44
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity	The activity of restricted shares of Class A common stock for the six months ended June 30, 2021 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Unvested at December 31, 2020 775,641 $ 1.77 Granted 10,728 1.66 Repurchased (19,728) 1.14 Vested (340,196) 1.62 Unvested at June 30, 2021 426,445 $ 1.92
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The Company has granted RSUs under the 2020 RSU Plan and the 2020 Plan. RSU activity for the six months ended June 30, 2021 is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Balance at December 31, 2020 491,318 $ 7.91 Granted 253,883 56.66 Vested (1,762) 43.39 Cancelled (3,543) 19.00 Balance at June 30, 2021 739,896 $ 24.50
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes the components of stock-based compensation recognized in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended Six Months Ended 2021 2020 2021 2020 Cost of revenue $ 344 $ — $ 747 $ — Research and development 1,098 170 2,187 351 Selling, general and administrative 4,989 638 9,535 1,036 Total stock-based compensation $ 6,431 $ 808 $ 12,469 $ 1,387

Commitments (Tables)

Commitments (Tables)	6 Months Ended
Commitments (Tables)	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As of June 30, 2021, future minimum commitments under the Company’s non-cancelable facility operating lease are as follows: Years ending December 31, (in thousands) 2021 (six months remaining) $ 398 2022 2,517 2023 3,642 2024 3,747 2025 3,856 Thereafter 27,013 Total $ 41,173

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable To Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data): Three Months Ended Six Months Ended 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ (16,616) $ (6,117) $ (33,045) $ (11,610) Denominator: Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 60,841,657 9,718,393 60,367,433 9,320,520 Net loss per share attributable to common stockholders, basic and diluted $ (0.27) $ (0.63) $ (0.55) $ (1.25)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis): Three Months Ended Six Months Ended 2021 2020 2021 2020 Convertible preferred stock — 29,026,787 — 29,026,787 Class A common stock options issued and outstanding 9,897,202 6,340,390 9,897,202 6,340,390 Restricted common stock subject to future vesting 426,445 1,886,297 426,445 1,886,297 Restricted stock units 739,896 101,510 739,896 101,510 Total 11,063,543 37,354,984 11,063,543 37,354,984

Organization, Consolidation and

Organization, Consolidation and Presentation of Financial Statements (Details) $ / shares in Units, $ in Thousands	Feb. 01, 2021USD ($)$ / sharesshares	Nov. 30, 2020	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Issuance of stock (in shares) \| shares	1,650,000
Public offering price (in usd per share) \| $ / shares	$ 67
Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs	$ 103,000			$ 102,959	$ 0
Offering transaction costs	$ 7,600		$ 7,591		$ 104
Reverse stock split, conversion ratio		0.4673
Cash, cash equivalents, and investments				517,800
Accumulated deficit				$ (88,406)		$ (55,361)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Basis of Presentation - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 370,675	$ 333,585
Restricted cash	524	343
Total cash, cash equivalents and restricted cash	$ 371,199	$ 333,928	$ 73,286	$ 17,828

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Basis of Presentation - Accounts Receivable, Net (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Allowance for credit loss	$ 0	$ 0

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments - Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total assets measured at fair value	$ 516,678	$ 431,863
Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market funds	369,580	333,585
U.S. Treasury securities	147,098	98,278
Total assets measured at fair value	516,678
Level 1 \| Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market funds	369,580	333,585
U.S. Treasury securities	0	0
Total assets measured at fair value	369,580	333,585
Level 2 \| Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market funds	0	0
U.S. Treasury securities	147,098	98,278
Total assets measured at fair value	147,098	98,278
Level 3 \| Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market funds	0	0
U.S. Treasury securities	0	0
Total assets measured at fair value	$ 0	$ 0

Fair Value Measurements and F_4

Fair Value Measurements and Fair Value of Financial Instruments - Unrealized Gain (Loss) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amortized Cost Basis	$ 516,712	$ 431,808
Unrealized Gains	10	57
Unrealized Losses	(44)	(2)
Fair Value	516,678	431,863
Money market funds
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amortized Cost Basis	369,580	333,585
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	369,580	333,585
U.S. Treasury securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amortized Cost Basis	147,132	98,223
Unrealized Gains	10	57
Unrealized Losses	(44)	(2)
Fair Value	$ 147,098	$ 98,278

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 1,833	$ 0
Finished goods	837	551
Total inventory	$ 2,670	$ 551

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 14,169		$ 14,169		$ 10,792
Less: accumulated depreciation and amortization	3,393		3,393		2,351
Property and equipment, net	10,776		10,776		8,441
Depreciation and amortization expense	600	$ 400	1,000	$ 700
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment	10,893		10,893		8,075
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	429		429		182
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	478		478		241
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	$ 2,369		$ 2,369		$ 2,294

Other Financial Statement Inf_5

Other Financial Statement Information - Schedule of Accrued Compensation (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Accrued compensation	$ 2,486	$ 2,866
Accrued professional services	374	1,074
Accrued property and equipment	361	0
Accrued inventory purchases	1,037	0
Restricted stock liability, current	383	484
Other	949	723
Total accrued expenses	$ 5,590	$ 5,147

Revenue and Deferred Revenue (D

Revenue and Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Aug. 31, 2019	Feb. 28, 2019
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 445		$ 445		$ 250
Research and Development Activties \| Biotechnology company
Deferred Revenue Arrangement [Line Items]
Deferred revenue							$ 900
Grant \| NH Grant
Deferred Revenue Arrangement [Line Items]
Deferred revenue		$ 900		$ 900		$ 1,100
Revenue recognized	$ 100	$ 100	$ 200	$ 200

Capital Stock and Stockholder_3

Capital Stock and Stockholders' Equity - Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)vote$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2020$ / sharesshares
Class of Stock [Line Items]
Common stock, authorized (in shares)		105,000,000
Preferred stock, authorized (in shares)		5,000,000		5,000,000
Proceeds from return of profit \| $	$ 11,400	$ 11,403	$ 0
Class A common stock
Class of Stock [Line Items]
Common stock, authorized (in shares)		94,000,000		94,000,000
Common stock, par value (usd per share) \| $ / shares		$ 0.00001		$ 0.00001
Voting rights (per share) \| vote		1
Class B common stock
Class of Stock [Line Items]
Common stock, authorized (in shares)		6,000,000		6,000,000
Common stock, par value (usd per share) \| $ / shares		$ 0.00001		$ 0.00001
Voting rights (per share) \| vote		10

Capital Stock and Stockholder_4

Capital Stock and Stockholders' Equity - Schedule of Common Stock by Class (Details) - shares	Jun. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Total common stock issued (in shares)	61,423,263	59,261,051
Total common stock outstanding (in shares)	61,423,263	59,261,051
Class A common stock
Class of Stock [Line Items]
Total common stock issued (in shares)	56,722,925	53,395,319
Total common stock outstanding (in shares)	56,722,925	53,395,319
Class B common stock
Class of Stock [Line Items]
Total common stock issued (in shares)	4,700,338	5,865,732
Total common stock outstanding (in shares)	4,700,338	5,865,732

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details)	Jun. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	5,965,116
Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	8,302,701
Class A common stock \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,195,327

Equity Incentive Plans - Activi

Equity Incentive Plans - Activity of Stock Options for the Period (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021
Options Outstanding
Beginning balance (in shares)	9,551,105
Options granted (in shares)	1,015,699
Options exercised (in shares)	(530,178)
Options cancelled and forfeited (in shares)	(139,424)
Ending balance (in shares)	9,897,202
Vested and exercisable (in shares)	2,128,772
Weighted Average Exercise Price
Beginning balance (in shares)	$ 5.55
Options granted (in usd per share)	54.65
Options exercised (in usd per share)	0.77
Options cancelled and forfeited (in usd per share)	18.81
Ending balance (in shares)	10.66
Vested and exercisable (in usd per share)	$ 3.44

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock Option Activity (Details) - Restricted Stock Options	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Number of Shares
Beginning balance (in shares) \| shares	775,641
Granted (in shares) \| shares	10,728
Repurchased (in shares) \| shares	(19,728)
Vested (in shares) \| shares	(340,196)
Ending balance (in shares) \| shares	426,445
Weighted-Average Grant Date Fair Value
Beginning balance (in usd per share) \| $ / shares	$ 1.77
Granted (in usd per share) \| $ / shares	1.66
Repurchased (in usd per share) \| $ / shares	1.14
Vested (in usd per share) \| $ / shares	1.62
Ending balance (in usd per share) \| $ / shares	$ 1.92

Equity Incentive Plans - RSU Ac

Equity Incentive Plans - RSU Activity for the Period (Details) - Restricted stock units	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Restricted Stock Units
Beginning balance (in shares) \| shares	491,318
Granted (in shares) \| shares	253,883
Vested (in shares) \| shares	(1,762)
Cancelled (in shares) \| shares	(3,543)
Ending balance (in shares) \| shares	739,896
Weighted-Average Grant Date Fair Value
Beginning balance (in usd per share) \| $ / shares	$ 7.91
Granted (in usd per share) \| $ / shares	56.66
Vested (in usd per share) \| $ / shares	43.39
Cancelled (in usd per share) \| $ / shares	19
Ending balance (in usd per share) \| $ / shares	$ 24.50

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Based Compensation Allocation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 6,431	$ 808	$ 12,469	$ 1,387
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	344	0	747	0
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,098	170	2,187	351
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 4,989	$ 638	$ 9,535	$ 1,036

Commitments - Facility Lease Ag

Commitments - Facility Lease Agreement Additional Information (Details) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Apr. 30, 2021ft²	Dec. 31, 2020USD ($)
Other Commitments [Line Items]
Not yet commenced, renewal term	127 months 15 days		127 months 15 days		127 months 15 days
Annual base rent	$ 0.9
Abatement period	9 months
Lease payments, annual increase, final year total	$ 1.2
Tenant incentives	$ 2.4
Current renewal term	5 years		5 years		5 years
Amount of square footage \| ft²						25,000
Lease term						11 years
Rent expense		$ 0.6	$ 0.2	$ 0.8	$ 0.3
Facility Lease Agreement Letter of Credit \| Letter of Credit
Other Commitments [Line Items]
Letter of credit issued		$ 0.5		$ 0.5			$ 0.5

Commitment and Contingencies -

Commitment and Contingencies - Minimum Commitments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021 (six months remaining)	$ 398
2022	2,517
2023	3,642
2024	3,747
2025	3,856
Thereafter	27,013
Total	$ 41,173

Commitments - Purchase Commitme

Commitments - Purchase Commitments (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Purchase obligations outstanding	$ 5.1	$ 3.1

Prognomiq, Inc. (Details)

Prognomiq, Inc. (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Other receivables	$ 0.4	$ 0.1

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable To Common Stockholders - Computation of EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss attributable to common stockholders, basic	$ (16,616)	$ (6,117)	$ (33,045)	$ (11,610)
Net loss attributable to common stockholders, diluted	$ (16,616)	$ (6,117)	$ (33,045)	$ (11,610)
Denominator:
Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic (in shares)	60,841,657	9,718,393	60,367,433	9,320,520
Weighted-average common shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	60,841,657	9,718,393	60,367,433	9,320,520
Net loss per share available to common shareholders, basic (in usd per share)	$ (0.27)	$ (0.63)	$ (0.55)	$ (1.25)
Net loss per share available to common shareholders, diluted (in usd per share)	$ (0.27)	$ (0.63)	$ (0.55)	$ (1.25)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable To Common Stockholders - Potentially Dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	11,063,543	37,354,984	11,063,543	37,354,984
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	29,026,787	0	29,026,787
Class A common stock options issued and outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,897,202	6,340,390	9,897,202	6,340,390
Restricted common stock subject to future vesting
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	426,445	1,886,297	426,445	1,886,297
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	739,896	101,510	739,896	101,510